FDA Clearance Tracker · P100034-S015
OPTUNE
Last checked: Nov 20, 2026Latest source record: Jul 13, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Jul 13, 2016
Approved
Time to decision
204 days
Received Dec 22, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P100034-S015
- Device name
- OPTUNE
- Applicant
- Novocure, GmbH
- Applicant location
- Baar
- Received
- Dec 22, 2015
- Decided
- Jul 13, 2016
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P100034
Device type
- Device class
- Class III
- Specialty
- Neurology & Neurosurgery
FDA's approval statement
As written in FDA's record.
Approval for a smaller, lighter weight version of the original Optune System, referred to as the Optune System (NovoTTF-200A System).
Source documents
Other decisions for Novocure, GmbH
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Optune PaxBreakthroughPMA
P250034 · Decided Feb 11, 2026 · 180 days after receipt
Device type: Low Electric Field Generator for Pancreatic Cancer Treatment (SHC) · General & Plastic Surgery
- Optune LuaPMA
P230042 · Decided Oct 15, 2024 · 305 days after receipt
Device type: Electrical tumor treatment fields for non-small cell lung cancer (SDA) · Anesthesiology & Respiratory
- OPTUNE (FORMERLY THE NOVOTTF-100A SYSTEM)PMA supplement
P100034-S013 · Decided Oct 5, 2015 · 178 days after receipt · Panel Track
Device type: Stimulator, low electric field, tumor treatment (NZK) · Neurology & Neurosurgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.